PSMA-dRT: Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer
Study Details
Study Description
Brief Summary
This randomized phase III trial studies the success rate of definitive radiation therapy (dRT) for prostate cancer (PCa) with or without planning based on PSMA PET. PSMA- PET-based dRT, may improve radiation therapy planning and patient selection for dRT, and potentially improve its outcome compared to dRT without PSMA PET (standard dRT).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Phase 3 |
Detailed Description
PRIMARY OBJECTIVE:
- To compare the outcome of patients with unfavorable intermediate (IR) and high-risk (HR) prostate cancer (PCa) after standard dRT versus prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-based dRT.
OUTLINE: Patients are randomized to 1 of 2 arms. In both arms, no other primary treatment should be given before RT.
Arm I: Patients do not undergo PSMA PET for dRT planning. Patients undergo standard of care dRT at the discretion of the treating radiation oncologist.
Arm II: Patients undergo PSMA PET for dRT planning. Patients then undergo dRT at the discretion of the treating radiation oncologist, who receives the PSMA PET result and images.
After completion of dRT, clinical follow-up of patients with their treating radiation oncologist will be obtained for 5 years. The investigators will rely on the medical records obtained from the treating physicians as the primary source of outcome data.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Arm I (dRT) 150 Patients undergo standard dRT at the discretion of the treating radiation oncologist. Patient does not undergo PSMA PET for RT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. No other primary treatment can be given before dRT. If a patient assigned to the control arm undergo a PSMA PET scan at another institution he will be discontinued from the study. |
Radiation: Radiation Therapy
Undergo standard of care definitive radiation therapy
Other Names:
|
| Experimental: Arm II (18F-DCFPyL, PET/CT, dRT) 162 Patient undergoes PSMA PET with 18F-DCFPyL for dRT planning. Any other imaging is allowed, including CT/BS/MR/PET depending on local practice. Patients then undergo dRT at the discretion of the treating radiation oncologist, who receives PSMA PET results and images. No other primary treatment can be given before RT. |
Procedure: Computed Tomography
Undergo whole body PET/CT
Other Names:
Other: Fluorine F 18 DCFPyL
Given IV
Other Names:
Procedure: Positron Emission Tomography
Undergo whole body PET/CT
Other Names:
Radiation: Radiation Therapy
Undergo standard of care definitive radiation therapy
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Success rate of definitive radiation therapy (dRT) [From date of randomization to first occurrence of progression, assessed up to 5 years]
Will be measured as progression-free survival after initiation of dRT. Progression is defined as (whichever occurs first): A biochemical recurrence defined as a rise by 2 ng/mL or more above the nadir prostate specific antigen (PSA) (defined as the lowest PSA achieved) after radiotherapy with or without short-term hormonal therapy, appearance of metastasis or loco-regional recurrence (diagnosed by any imaging or biopsy), initiation of any new salvage therapy or death from any cause. Survival curves will be constructed using the Kaplan-Meier method.
Secondary Outcome Measures
- Loco-regional progression free survival [Up to 5 years after the date of randomization]
Diagnosis of local recurrence or pelvic nodal disease (N1) can be obtained by any imaging or biopsy.
- Metastasis-free survival after initiation of radiation therapy (RT) [Up to 5 years after the date of randomization]
Diagnosis of extra-pelvic metastatic (M1) disease can be obtained by any imaging or biopsy.
- Overall survival [Up to 5 years after the date of randomization]
- Change in initial treatment intent [Baseline up to 5 years after the date of randomization]
Will estimate the proportion of subjects in the prostate-specific membrane antigen (PSMA) group that have a change in the initial treatment intent and compute a 95% confidence interval for that proportion.
- PSMA positron emission tomography (PET) derived predictors of progression-free survival [Up to 5 years after the date of randomization]
Will use Cox-proportional hazards regression to assess PSMA PET predictors of progression-free survival.
- PSMA PET derived predictors of overall survival [Up to 5 years after the date of randomization]
Will use Cox-proportional hazards regression to assess PSMA PET predictors of overall survival.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult male 18 years or older
-
Histopathologically-proven PCa
-
Unfavorable IR to HR disease:
-
Prostate specific antigen (PSA) >= 10 ng/mL
-
Or cT-stage >= 2b
-
Or Gleason grade 3 (4+3=7) or higher
-
Or Gleason grade 2 (3+4=7) AND >= 50% positive biopsy cores
-
Or Decipher Score >= 0.45
-
Treating radiation oncologist intends to incorporate PSMA PET findings into the radiotherapy plan, if patient undergoes PSMA PET (intervention arm 2)
-
Provision of signed and dated informed consent form
-
Stated willingness to comply with all study procedures and availability for the duration of the study
Exclusion Criteria:
-
Less than 18 years old at the time of investigational product administration
-
Extra-pelvic metastasis (M1 disease) on any imaging or biopsy done before randomization
-
Prior PSMA PET
-
Prior pelvic RT
-
Contraindications to radiotherapy (including active inflammatory bowel disease)
-
Concurrent or prior surgery or systemic therapy for PCa at the time of randomization
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California | United States | 90095 |
Sponsors and Collaborators
- Jonsson Comprehensive Cancer Center
- Progenics Pharmaceuticals, Inc.
Investigators
- Principal Investigator: Jeremie Calais, UCLA / Jonsson Comprehensive Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 20-000378
- NCI-2020-03445